secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2022-06-14T23:59:59+00:00
Accession:  0001493152-22-016671
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma shareholders approve all proposals including authorized share reduction and 2022 Omnibus Incentive Plan
--------------------------------------------------------------------------------

- Elected directors Breen, Shrotriya, and Wendel with majority support (for votes 58-61% of shares present).
- Ratified Weinberg & Company as independent auditor for FY2022 (19.7M for, 0.2M against).
- Approved 2022 Omnibus Incentive Plan authorizing up to 5M shares of common stock.
- Approved amendment to reduce authorized common stock from 750M to 250M shares (19.6M for).
- Advisory say-on-pay passed (63.7% of votes cast) and frequency set at 1 year (11.9M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315222016671/0001493152-22-016671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315222016671/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-016671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer